DYNAMICS OF QUALITY OF LIFE IN ANEMIC PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS TREATED WITH RED BLOOD CELL TRANSFUSIONS AND ERYTHROPOIESIS-STIMULATING AGENTS
(Abstract release date: 05/19/16)
EHA Library. Romanenko N. 06/09/16; 135012; PB2112
Mr. Nikolay Romanenko
Contributions
Contributions
Abstract
Abstract: PB2112
Type: Publication Only
Background
Anemia is a frequent complication of lymphoproliferative disorders (LPD) and antitumor therapy decreasing overall survival rate and Quality of Life (QoL). Anemia’s pathogenesis is based on suppression by proinflammatory cytokines, decreasing erythroid precursor’s sensitivity to serum erythropoietin and the myelosuppressive effects of chemotherapy. The main methods of anemia’s correction are red blood cells transfusions (RBCsT) and using of erythropoiesis-stimulating agents (ESA). Both of them increase hemoglobin concentration and improve QoL. However RBCsT are used in patients with severe anemia and ESA are used to treat mild or middle anemia therefore alteration of QoL after correction may differ.
Aims
The aim of the work was to compare dynamics of QoL in LPD patients during anemia’s correction using RBCsT and applying of ESA.
Methods
In this study anemic patients with lymphoproliferative disorders were included. The efficacy of anemia’s correction by means RBCsT and applying of ESA was assessed in the base of clinical, laboratory methods and Quality of Life by using the questionnaire FACT-An.
Results
In the first group patients (n=54) with severe or middle anemia with initial Hb concentration of 70.0±1.6 g/l were included. To correct anemia they were prescribed RBCsT. After transfusions (Me=3 Units) the Hb level was increased up to 93.1±1.2 g/l. In the second group patients (n=77) with mild or middle anemia with initial Hb concentration of 88.4±1.4 g/l were included. All these patients were treated with erythropoiesis-stimulating agents. After ESA-therapy a positive response as increase of Hb concentration ≥20 g/l was in 52 (67.5%) out of 77 patients. Herewith the Hb concentration of patients with positive response increased up to 123.1±2.4 g/l. Analysis of dynamics of QoL patients after RBSsT revealed the significant alteration in “Physical well-being”, “Emotional well-being”, “Functional well-being” and “Anemia” scales. After EPO-therapy significant alteration were revealed in “Physical well-being” and “Anemia” scales. However in comparative analysis of QoL in both groups of patients the maximal improvement was revealed in the scale of “Physical well-being” (in the first group after RBCsT it was from 12.9±0.7 to 11.0±08 points; p<0.001, in the second one after ESA-therapy – from 11.6±0.7 to 9.6±0.7 points; p<0.02) and scale of “Anemia”: after RBCsT it was from 41.1±2.0 to 34.2±2.1 points (p<0.001), after ESA-therapy – from 34.5±1.7 to 30.1±1.6 points (p<0.001).
Conclusion
RBCsT and ESA-therapy may significantly increase the Hb concentration and improve Quality of Life. However QoL of patients after ESA-therapy was better than after RBCsT because Hb concentration was achieved to normal level after applying erythropoiesis-stimulating agents. Nevertheless both methods for anemia correction are effective and ESA-therapy may be prescribed to prolong treatment of anemia after RBCsT.
Session topic: E-poster
Keyword(s): Anemia, Erythropoietin, Red blood cell, Transfusion
Type: Publication Only
Background
Anemia is a frequent complication of lymphoproliferative disorders (LPD) and antitumor therapy decreasing overall survival rate and Quality of Life (QoL). Anemia’s pathogenesis is based on suppression by proinflammatory cytokines, decreasing erythroid precursor’s sensitivity to serum erythropoietin and the myelosuppressive effects of chemotherapy. The main methods of anemia’s correction are red blood cells transfusions (RBCsT) and using of erythropoiesis-stimulating agents (ESA). Both of them increase hemoglobin concentration and improve QoL. However RBCsT are used in patients with severe anemia and ESA are used to treat mild or middle anemia therefore alteration of QoL after correction may differ.
Aims
The aim of the work was to compare dynamics of QoL in LPD patients during anemia’s correction using RBCsT and applying of ESA.
Methods
In this study anemic patients with lymphoproliferative disorders were included. The efficacy of anemia’s correction by means RBCsT and applying of ESA was assessed in the base of clinical, laboratory methods and Quality of Life by using the questionnaire FACT-An.
Results
In the first group patients (n=54) with severe or middle anemia with initial Hb concentration of 70.0±1.6 g/l were included. To correct anemia they were prescribed RBCsT. After transfusions (Me=3 Units) the Hb level was increased up to 93.1±1.2 g/l. In the second group patients (n=77) with mild or middle anemia with initial Hb concentration of 88.4±1.4 g/l were included. All these patients were treated with erythropoiesis-stimulating agents. After ESA-therapy a positive response as increase of Hb concentration ≥20 g/l was in 52 (67.5%) out of 77 patients. Herewith the Hb concentration of patients with positive response increased up to 123.1±2.4 g/l. Analysis of dynamics of QoL patients after RBSsT revealed the significant alteration in “Physical well-being”, “Emotional well-being”, “Functional well-being” and “Anemia” scales. After EPO-therapy significant alteration were revealed in “Physical well-being” and “Anemia” scales. However in comparative analysis of QoL in both groups of patients the maximal improvement was revealed in the scale of “Physical well-being” (in the first group after RBCsT it was from 12.9±0.7 to 11.0±08 points; p<0.001, in the second one after ESA-therapy – from 11.6±0.7 to 9.6±0.7 points; p<0.02) and scale of “Anemia”: after RBCsT it was from 41.1±2.0 to 34.2±2.1 points (p<0.001), after ESA-therapy – from 34.5±1.7 to 30.1±1.6 points (p<0.001).
Conclusion
RBCsT and ESA-therapy may significantly increase the Hb concentration and improve Quality of Life. However QoL of patients after ESA-therapy was better than after RBCsT because Hb concentration was achieved to normal level after applying erythropoiesis-stimulating agents. Nevertheless both methods for anemia correction are effective and ESA-therapy may be prescribed to prolong treatment of anemia after RBCsT.
Session topic: E-poster
Keyword(s): Anemia, Erythropoietin, Red blood cell, Transfusion
Abstract: PB2112
Type: Publication Only
Background
Anemia is a frequent complication of lymphoproliferative disorders (LPD) and antitumor therapy decreasing overall survival rate and Quality of Life (QoL). Anemia’s pathogenesis is based on suppression by proinflammatory cytokines, decreasing erythroid precursor’s sensitivity to serum erythropoietin and the myelosuppressive effects of chemotherapy. The main methods of anemia’s correction are red blood cells transfusions (RBCsT) and using of erythropoiesis-stimulating agents (ESA). Both of them increase hemoglobin concentration and improve QoL. However RBCsT are used in patients with severe anemia and ESA are used to treat mild or middle anemia therefore alteration of QoL after correction may differ.
Aims
The aim of the work was to compare dynamics of QoL in LPD patients during anemia’s correction using RBCsT and applying of ESA.
Methods
In this study anemic patients with lymphoproliferative disorders were included. The efficacy of anemia’s correction by means RBCsT and applying of ESA was assessed in the base of clinical, laboratory methods and Quality of Life by using the questionnaire FACT-An.
Results
In the first group patients (n=54) with severe or middle anemia with initial Hb concentration of 70.0±1.6 g/l were included. To correct anemia they were prescribed RBCsT. After transfusions (Me=3 Units) the Hb level was increased up to 93.1±1.2 g/l. In the second group patients (n=77) with mild or middle anemia with initial Hb concentration of 88.4±1.4 g/l were included. All these patients were treated with erythropoiesis-stimulating agents. After ESA-therapy a positive response as increase of Hb concentration ≥20 g/l was in 52 (67.5%) out of 77 patients. Herewith the Hb concentration of patients with positive response increased up to 123.1±2.4 g/l. Analysis of dynamics of QoL patients after RBSsT revealed the significant alteration in “Physical well-being”, “Emotional well-being”, “Functional well-being” and “Anemia” scales. After EPO-therapy significant alteration were revealed in “Physical well-being” and “Anemia” scales. However in comparative analysis of QoL in both groups of patients the maximal improvement was revealed in the scale of “Physical well-being” (in the first group after RBCsT it was from 12.9±0.7 to 11.0±08 points; p<0.001, in the second one after ESA-therapy – from 11.6±0.7 to 9.6±0.7 points; p<0.02) and scale of “Anemia”: after RBCsT it was from 41.1±2.0 to 34.2±2.1 points (p<0.001), after ESA-therapy – from 34.5±1.7 to 30.1±1.6 points (p<0.001).
Conclusion
RBCsT and ESA-therapy may significantly increase the Hb concentration and improve Quality of Life. However QoL of patients after ESA-therapy was better than after RBCsT because Hb concentration was achieved to normal level after applying erythropoiesis-stimulating agents. Nevertheless both methods for anemia correction are effective and ESA-therapy may be prescribed to prolong treatment of anemia after RBCsT.
Session topic: E-poster
Keyword(s): Anemia, Erythropoietin, Red blood cell, Transfusion
Type: Publication Only
Background
Anemia is a frequent complication of lymphoproliferative disorders (LPD) and antitumor therapy decreasing overall survival rate and Quality of Life (QoL). Anemia’s pathogenesis is based on suppression by proinflammatory cytokines, decreasing erythroid precursor’s sensitivity to serum erythropoietin and the myelosuppressive effects of chemotherapy. The main methods of anemia’s correction are red blood cells transfusions (RBCsT) and using of erythropoiesis-stimulating agents (ESA). Both of them increase hemoglobin concentration and improve QoL. However RBCsT are used in patients with severe anemia and ESA are used to treat mild or middle anemia therefore alteration of QoL after correction may differ.
Aims
The aim of the work was to compare dynamics of QoL in LPD patients during anemia’s correction using RBCsT and applying of ESA.
Methods
In this study anemic patients with lymphoproliferative disorders were included. The efficacy of anemia’s correction by means RBCsT and applying of ESA was assessed in the base of clinical, laboratory methods and Quality of Life by using the questionnaire FACT-An.
Results
In the first group patients (n=54) with severe or middle anemia with initial Hb concentration of 70.0±1.6 g/l were included. To correct anemia they were prescribed RBCsT. After transfusions (Me=3 Units) the Hb level was increased up to 93.1±1.2 g/l. In the second group patients (n=77) with mild or middle anemia with initial Hb concentration of 88.4±1.4 g/l were included. All these patients were treated with erythropoiesis-stimulating agents. After ESA-therapy a positive response as increase of Hb concentration ≥20 g/l was in 52 (67.5%) out of 77 patients. Herewith the Hb concentration of patients with positive response increased up to 123.1±2.4 g/l. Analysis of dynamics of QoL patients after RBSsT revealed the significant alteration in “Physical well-being”, “Emotional well-being”, “Functional well-being” and “Anemia” scales. After EPO-therapy significant alteration were revealed in “Physical well-being” and “Anemia” scales. However in comparative analysis of QoL in both groups of patients the maximal improvement was revealed in the scale of “Physical well-being” (in the first group after RBCsT it was from 12.9±0.7 to 11.0±08 points; p<0.001, in the second one after ESA-therapy – from 11.6±0.7 to 9.6±0.7 points; p<0.02) and scale of “Anemia”: after RBCsT it was from 41.1±2.0 to 34.2±2.1 points (p<0.001), after ESA-therapy – from 34.5±1.7 to 30.1±1.6 points (p<0.001).
Conclusion
RBCsT and ESA-therapy may significantly increase the Hb concentration and improve Quality of Life. However QoL of patients after ESA-therapy was better than after RBCsT because Hb concentration was achieved to normal level after applying erythropoiesis-stimulating agents. Nevertheless both methods for anemia correction are effective and ESA-therapy may be prescribed to prolong treatment of anemia after RBCsT.
Session topic: E-poster
Keyword(s): Anemia, Erythropoietin, Red blood cell, Transfusion
{{ help_message }}
{{filter}}